Pharmacological characterization of LY335979: A potent cyclopropyldibenzosuberane modulator of P-glycoprotein

Advances in Enzyme Regulation

Volumn 37, Issue , 1997, Pages 335-347

  Starling, James J ^a   Shepard, Robert L ^a   Cao, Jin ^a   Law, Kevin L ^a   Norman, Bryan H ^a   Kroin, Julian S ^a   Ehlhardt, William J ^a   Baughman, Todd M ^a   Winter, Mark A ^a   Bell, Michael G ^a   Shih, Chuan ^a   Gruber, Joseph ^a   Elmquist, William F ^b   Dantzig, Anne H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; ISOQUINOLINE DERIVATIVE; LY 335979; LY335979; QUINIDINE; QUINOLINE DERIVATIVE; TAXOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RESISTANCE; CELL CULTURE; CONFERENCE PAPER; CYTOTOXICITY; DRUG RESEARCH; DRUG RESISTANCE; DRUG STRUCTURE; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; MOUSE; MOUSE STRAIN; MULTIDRUG RESISTANCE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; DIBENZOCYCLOHEPTENES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; ISOQUINOLINES; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; QUINIDINE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED; VERAPAMIL;

ANIMALIA;

EID: 0030769833     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(96)00021-0     Document Type: Conference Paper

References (19)

1. 1. J. MURREN and V. DEVITA, Another look at multidrug resistance, Princ. Pract. Oncol. 9, 1-11 (1995).
2. 2. C. SHUSTIK, W. DALTON and P. GROS, P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance, and modulation, Molec. Aspects Med. 16, 1-78 (1995).
3. 3. L. GOLDSTEIN, Clinical reversal of drug resistance, Curr. Prob. Cancer 19, 67-124 (1995).
4. 4. J. FORD and W. HAIT, Pharmacology of drugs that alter multidrug resistance in cancer, Pharmacol. Rev. 42, 155-199 (1990).
5. 5. J. FORD and W. HAIT, Pharmacologic circumvention of multidrug resistance, Cytotechnology 12, 171-212 (1993).
6. 6. B. LUM, G. FISHER, N. BROPHY, A. YAHANDA, K. ADLER, S. KAUBISCH, J. HALSEY and B. SIKIC, Clinical trials of modulation of multidrug resistance, Cancer Supplement 72, 3502-3514 (1993).
7. 7. G. TOFFOLI, F. SIMONE, G. CORONA, M. RASCHACK, B. CAPPELLETTO, M. GIGANTE and M. BOIOCCHI, Structure-activity relationship of verapamil analogs and reversal of multidrug resistance, Biochem. Pharmacol. 50, 1245-1255 (1995).
8. 8. D. BOESCH, K. MULLER, A. POURTIER-MANZANEDO and F. LOOR, Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunesuppressive cyclosporin derivative, Exptl. Cell Res. 196, 26-32 (1991).
9. 9. D. BOESCH, C. GAVERIAUX, B. JACHEZ, A. POURTIER-MANZANEDO, P. BOLLINGER and F. LOOR, In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833, Cancer Res. 51, 4226-4233 (1991).
10. 10. H. PEARCE, A. SAFA, N. BACH, M. WINTER, M. CIRTAIN and W. BECK, Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance, Proc. Natl Acad Sci. USA 86, 5128-5132 (1989).
11. 11. W. SATO, N. FUKUZAWA, T. SUZUKI, K. YUSA and T. TSURUO, Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073, Cancer Res. 51, 2420-2424 (1991).
12. 12. A. PIERRE, T. DUNN, L. KRAUS-BERTHIER, S. LEONCE, D. SAINT-DIZLER, G. REGNIER, A. DHALNAUT, M. BERLION, J.-P. BIZZARI and B. ATASSI, In vitro and in vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative, Invest. New Drugs 10, 137-148 (1992).
13. 13. F. HYAFIL, C. VERGELY, P. DU VIGNAUD and T. GRAND-PERRET, In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer Res. 53, 4595-4602 (1993).
14. 14. D. SLATE, N. BRUNO, S. CASEY, N. ZUTSHI, L. GARVIN, H. WU and J. PFISTER, RS-33295-198, a novel, potent modulator of P-glycoprotein-mediated multidrug resistance, Anticancer Res. 15, 1-4 (1995).
15. 15. J. PFISTER, F. MAKRA, A. MUEHLDORF, H. WU, J. NELSON, P. CHEUNG, N. BRUNO, S. CASEY, N. ZUTSHI and D. SLATE, Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents, Bioorg. Med. Chem. Lett. 5, 2473-2476 (1995).
16. 16. A. DANTZIG, R. SHEPARD, J. CAO, K. LAW, W. EHLHARDT, T. BAUGHMAN, T. BUMOL and J. STARLING, Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979, Cancer Res. 56, 4171-4179 (1996).
17. 17. N. VARKI, R. REISFELD and L. WALKER, Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies, Cancer Res. 44, 681-687 (1984).
18. 18. S. LONGNECKER, R. DONEHOWER, A. CATES, T.-L. CHEN, R. BRUNDRETT, L. GROCHOW, D. ETTINGER and M. COLVIN, High-performance liquid chromatography assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial, Cancer Treat. Rep. 71, 53-59 (1987).
19. 19. P. BORST and A. SCHINKEL, What have we learnt thus far from mice with disrupted P-glycoprotein genes?, Eur. J. Cancer 32A, 985-990 (1996).